EU Funding Programme
EUCAPA is designed to train patients and their representatives in Health Technology Assessment (HTA) – the multidisciplinary and systematic process that evaluates the added value of a health technology in comparison to other existing or new ones.
Through EUCAPA, patients and their representatives will gain knowledge and skills to participate in HTA decision-making processes and advocate for equitable access to innovative treatments for rare diseases.
Focusing mostly – but not exclusively – on people living with cancer and people who need advanced therapy medicinal products (ATMPs), EUCAPA is set to last two years and will offer three types of trainings:
- Online introductory training for the larger patient community and patient organisations who need to know more about HTA to participate in joint clinical assessments (JCAs) and scientific consultations (JSCs).
- Online fast-track training enabling patients to gain the essential skills needed to participate as patient experts, which will be aimed at those who will participate in JCAs and JSCs at short notice.
- In-person extended training that will further develop concepts, skills and knowledge from the two previous trainings.
EURORDIS-Rare Diseases Europe is a unique, non-profit alliance of over 1,000 rare disease patient organisations from 74 countries that work together to improve the lives of the 30 million people living with a rare disease in Europe.
The European Patients’ Forum (EPF) is an independent non-profit, non-governmental umbrella organisation of patient organisations across Europe and across disease-areas. EPF’s 78 members include disease-specific patient groups active at EU level and national coalitions of patients.
UMIT TIROL has specialised in new vocational areas in health sciences and health technology and provides guidance to health policy decision makers and the public.
- The total budget is €499,671
- The grant is €299,803
- The schedule is March 2023 – March 2025